Generate Biomedicines, Inc. Common Stock vs. Johnson & Johnson
GENB
Generate Biomedicines, Inc. Common Stock
$16.14 -20.80%
VS JNJJohnson & Johnson
$270.00 -1.15%
Johnson & Johnson (JNJ) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| GENB | JNJ | |
|---|---|---|
| Market Cap | $2.62 billion | $658.24 billion |
| Revenue (TTM) | — | $97.93 billion |
| Net Income (TTM) | — | $21.04 billion |
JNJ leads on 1 of 1 size & scale factors.
Valuation
| GENB | JNJ | |
|---|---|---|
| P/E Ratio | — | 31.32 |
| Price / Book | 5.74 | 7.75 |
| Price / Sales | — | 6.72 |
GENB leads on 1 of 1 valuation factors.
Profitability
| GENB | JNJ | |
|---|---|---|
| Net Margin | — | 21.48% |
| Return on Equity | — | 24.76% |
GENB and JNJ split the profitability factors evenly.
Dividend
| GENB | JNJ | |
|---|---|---|
| Dividend Yield | — | 1.99% |
| Payout Ratio | — | 62.18 |
GENB and JNJ split the dividend factors evenly.
Risk & Sentiment
| GENB | JNJ | |
|---|---|---|
| Short Interest | 0.70% | 0.67% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: GENB overview, GENB financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.